Mefenamic Acid: Clinical Overview
Primary Indications
Mefenamic acid is FDA-approved for relief of mild to moderate pain in patients ≥14 years of age when therapy will not exceed one week (7 days), and for treatment of primary dysmenorrhea 1. Beyond these core indications, it has established roles in specific clinical scenarios.
Pain Management Applications
- Acute pain: Effective for postoperative pain, with an NNT of 4.0 (2.7-7.1) for at least 50% pain relief over 6 hours with a 500 mg dose 2
- Primary dysmenorrhea: Produces complete relief in 88.6% of patients when given as 500 mg every 8 hours for maximum 3 days during menstruation 3
- Dental pain, headache, postpartum pain: Recognized indications in clinical practice 4
Gynecological Applications
Mefenamic acid demonstrates specific utility for contraceptive-related bleeding irregularities:
- Cu-IUD users: 500 mg three times daily for 5 days significantly reduces heavy or prolonged menstrual bleeding 5
- Contraceptive implant users: 500 mg three times daily for 5 days achieves significant bleeding cessation within 7 days compared to placebo 5
- DMPA users: 5-day course effectively stops breakthrough bleeding 5
Pediatric Fever Management
Recent evidence supports mefenamic acid as a highly effective antipyretic in children, achieving normothermia in 1.99±0.47 hours with sustained effect for 61.92±11.52 hours 6. A 2022 randomized trial demonstrated that mefenamic acid 6 mg/kg produces faster temperature reduction and longer duration of action than standard-dose paracetamol (15 mg/kg), with comparable efficacy to high-dose paracetamol (20 mg/kg) 7. The pediatric consensus recommends it for children ≥6 months at 5 mg/kg three times daily 8.
Dosing Regimens
Adults
- Pain/dysmenorrhea: 500 mg every 8 hours, maximum 2000 mg/day (4×500 mg) 9, 10, 9
- Onset of action: 30 minutes 9, 10, 9
- Duration: Not to exceed 7 days for pain 1
Pediatrics
- Fever/pain: 5 mg/kg three times daily 8, 6
- Alternative dosing: 6 mg/kg for fever 7
- Age: ≥6 months (consensus recommendation) 8
Contraindications
Absolute contraindications per FDA labeling 1:
- Known hypersensitivity to mefenamic acid (including anaphylactic reactions, serious skin reactions)
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Setting of coronary artery bypass graft (CABG) surgery
Additional high-risk scenarios requiring avoidance:
- Active bleeding or bleeding disorders
- Severe renal impairment (CrCl <30 mL/min)
- Active peptic ulcer disease or GI bleeding
- Pregnancy (third trimester)
Adverse Effects and Safety Profile
Black Box Warnings 1
Cardiovascular thrombotic events: Increased risk of myocardial infarction and stroke, which can be fatal. Risk may occur early in treatment and increases with duration of use.
Gastrointestinal bleeding, ulceration, and perforation: Can occur at any time during use without warning symptoms. Elderly patients and those with prior peptic ulcer disease/GI bleeding are at greater risk.
Common Adverse Effects
- Gastrointestinal: Nausea, vomiting, gastritis, dyspepsia (most frequent) 9, 10, 9
- Renal toxicity: Nephrotoxicity with prolonged use 9, 10, 9
- CNS: Dizziness, headache 11
Critical Safety Considerations
Mefenamic acid has a narrower therapeutic window than other NSAIDs, with systemic toxicity occurring at relatively low doses above the maximum daily dose 12. This 2007 review concluded there is no reason to prefer mefenamic acid over other NSAIDs for routine use, given its less favorable tolerability profile with prolonged administration.
However, recent pediatric data (2025) demonstrates excellent safety with short-term use: no treatment-related adverse events or clinically significant laboratory abnormalities in 50 children treated for up to 3 days 6.
Monitoring Requirements
- Gastric protection: Recommended with prolonged NSAID use 10
- Renal function: Caution in patients at risk or taking nephrotoxic drugs 9, 10
- Bleeding risk: Vigilance in patients at risk of bleeding 9, 10
Clinical Positioning
For short-term use (≤7 days), mefenamic acid is effective and safe for pain, dysmenorrhea, and fever 1, 2, 6, 7. Its unique pharmacology—including preferential COX-2 inhibition, EP receptor blockade, and NLRP3 inflammasome inhibition—provides comprehensive symptom relief 8.
For routine pain management beyond one week or in dental practice, other NSAIDs should be preferred due to better tolerability 12. The drug's niche remains in gynecological applications (dysmenorrhea, contraceptive-related bleeding) and as an alternative antipyretic in pediatrics when paracetamol/ibuprofen are insufficient 5, 8, 3.
Key practice point: Always use the lowest effective dose for the shortest duration consistent with treatment goals, and never exceed 7 days for pain management 1.